News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sold Woke DEI stocks unfortunate plus selling my small cap Bios for BTC
$PRQR
Don't let the early pipeline make you weary.
$PRQR
Bought a tranche 1.50's today building a core holding here over the next few weeks on dips.
$PRQR
PRQR under $2
PRQR, under $2
SGMO 2.0 will see by the time anything gets to market its 10 years roughly still preclinical
Added a few more today flush with cash after the tax man has been dealt with. I just hope this doesn't see .50 Like Century Therapeutics one of the founders of CRSP is the CEO and Tim Walbert is on there board go figure!
500k shares will see wait and see where she goes before I add another 500k shares.
$PRQR
All indications are pre-clinical I hope they sell it sooner than later these guys really move slow. Lily was a strategic partner SCYX
PRQR Phase 1 data by year end probably end up being early 2026 to be realistic this company has lagged a bit. Be patient and add the dips.
SCYNEXIS is a biotechnology company focused on developing innovative treatments for serious fungal infections, and they have a collaboration with Eli Lilly, specifically around the development of fungerp technology for treating fungal infections. PRQR is a risky bet Lily partnered with SCYX 35 million market cap and it has become a dud-nothing is a sure thing here!
Added 207k shares today up too almost 390k more to go keep selling me your shares~
$PRQR
PRQR is an Eli Lilly oligonucleotide RNA Editing Platform 17.1% ownership New Next generation Platform with huge indications like obesity and cardiovascular diseases Lily will be able to manufacture these drugs for them. Never Seen Lily own so much of a small cap company and make milestone payments on them so soon. These Milestones so far will reach close to 4 Billion dollars and payments have commenced.
Eli Lilly made a 25M Royalty payment in 2024 vs. $3.9B in potential milestone payments so far 5 more indications lily totaling 15 indications and cash runway for over the next 2.5 years. “Lilly” has 95 appearances in their annual report.
PRQR has 2 founders plus chief CMO from Analyam the leader in RNAI 31 Billion company
1. Martin Maier, PhD
Martin Maier, PhD, joined our board in 2024. Dr. Maier currently serves as Senior Vice President, Oncology at Alnylam Pharmaceuticals. Dr. Maier joined Alnylam in 2006 and has contributed to the development of lipid nanoparticles and GalNAc conjugates, two clinically validated platforms for siRNA delivery, and the advancement of multiple therapeutic programs to development, which has resulted in the approval of five RNAi therapeutic to date.
2.Phillip D. Zamore, PhD
Phillip is a Howard Hughes Medical Institute Investigator, Gretchen Stone Cook Chair of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Chair of the RNA Therapeutics Institute at the University of Massachusetts Medical School. He is also a co-founder of Alnylam Pharmaceuticals
3.John Maraganore, PhD, joined as a strategic advisor to our Board in March 2022. He served as the founding Chief Executive Officer and a Director of Alnylam from 2002 to 2021, where he built the company from early platform research on RNA interference through global approval and commercialization of the first four RNAi therapeutic medicines, ONPATTRO®, GIVLAARI®, OXLUMO®, and Leqvio®. At Alnylam, he also led the company’s value creation strategy, building $ 25.0 billion in market capitalization
No other company has all key executives of Alnylam connected to any team in Biotech.
lastly
A. Peter Beal, PhD
Peter was appointed as ProQR's Chief ADAR Scientist in December 2024. Peter is a Professor in the Department of Chemistry at the University of California at Davis and Director of the NIH-funded UC Davis Chemical Biology Graduate Program. For over 25 years, work in the Beal laboratory has advanced understanding of the structures and mechanism of action for the ADAR enzymes responsible for adenosine to inosine RNA editing in humans. In addition, his group has led in the development of structure-guided methods for optimizing chemically modified oligonucleotides for recruitment of RNA-binding proteins including ADARs. Beal teaches organic chemistry at the undergraduate level and several classes in nucleic acids chemistry and chemical biology at the graduate level. He has authored over 100 peer-reviewed publications in the field of RNA chemical biology and mentored over 50 Ph.D. and M.S. degree students.
I will be buying up shares up to $2.00 today.
My thoughts are hold for 2 years you have a high probability of success maximizing profits and a buyout from LILY or Alnylam Pharmaceuticals. for 1.5-2 Billion similar to Roche buying Poseida for a total of 1.5 Billion last year early stage gene editing company.
PRQR has close to 30 Indications in their pipeline 15 of them with ELI Lilly
$PRQR
54.36% owned by Institutions[ thats not including Eli Lilly & Van Herk thats another 27.2% =81.5%+ Insiders 14.5% 95% dirk haussecker north 2% M28 Capital 1%
98% of PRQR shares are accounted for
Adage Capital Partners GP L.L.C. 9.6M Dec 31, 2024 11.76% 16,707,967
Privium Fund Management B.V. 4.99M Dec 31, 2024 6.10% 8,675,001
Woodline Partners LP 3.56M Dec 31, 2024 4.35% 6,189,181
Affinity Asset Advisors, Llc 2.83M Dec 31, 2024 3.46% 4,915,500
Millennium Management Llc 2.83M Dec 31, 2024 3.46% 4,919,467
UBS Group AG 2.31M Dec 31, 2024 2.83% 4,019,487
Sio Capital Management, LLC 2.05M Dec 31, 2024 2.52% 3,574,991
Kynam Capital Management, LP 1.75M Dec 31, 2024 2.14% 3,045,000
Siren, L.L.C. 1.57M Dec 31, 2024 1.93% 2,740,500
DAFNA Capital Management, LLC 1.57M Dec 31, 2024 1.92% 2,727,556
Eli Lilly owns 16.1% check the filings if you don't believe me not included in institutional ownership Largest Pharma company in the world
Van Herk Investments B.V.owns 11.1% not included in institutional ownership (one of the largest real estate holders in Europe)
=81.6% roughly including Lilly & Van Herk
Insiders own 14.5%
96% of the shares are spoken for remember dirk haussecker owns 2% and M28 Capital owns over a million shares and Keeps adding shares.
There are no shares Floating around. If you can see the asymmetric upside here place your bets. I bought a chunk of the shares today and need another 863k shares.
WVE 1.6 Billion
PRQR 184 Million superior technology Patent protection Partnerships and Team
$PRQR
Dirk Haussecker RNA editing expert owns north of 2% of PRQR shares!
Disclosure: I own >2% of the company stock. This blog post is not meant as a stock recommendation, but to provide greater visibility and transparency of ProQR and ADAR RNA Editing. Dirk Haussecker
Eli Lilly owns 16.5% of the shares
I will build a million share core position here over the coming weeks!
$PRQR
Starting to Buy PRQR this morning this company is worth more than WVE
Eli Lilly owns close to 20% of the company and their funded through 2027 IP Patents = BULLET PROOF
they get bought by LLY or ALNY for 1.5-2 Billion in the next 24 months or less
IP is bullet proof for oligonucleotide editing space they will receive royalties from others in the space.
Only small cap with 100x if they decide not to sell their soon to be conglomerate funded through 2027 with Lily starting to pay them on 3.9 Billion partnership in place with PRQR
This reminds me of Horizon Therapeutics sold for 28 Billion and Stock price history for Horizon Therapeutics (HZNP). Highest end of day price: $119.91 USD on 2021-10-29. Lowest end of day price: $1.99 USD on 2013-03-04.
Similar Story PRQR CEO has a son with a rare disease like Horizons PRQR is backed by the most powerful biotech company in the world LLY & the king of RNAI Alnylam what a great fit PRQR would be for either powerhouse.
RNA editing for 30 Indications
All founders from ALNY on the PRQR board
$PRQR
Doubling my position here today!
Love this technology and team
$PRQR
PRQR is WVE 2.0
Glad I loaded the day before the break out!
100k shares long Love the Lily connection and brain power from ALNY at PRQR very early pipeline buy out sooner than later.
Lily owns over 16% of PRQR
$PRQR
PRQR under $3
PRQR under $2
PRQR under $2
PRQR under $2
PRQR under $2
PRQR under $2
Ya....
$PRQR Strong break up the chart..on watch next week
https://stockcharts.com/c-sc/sc?s=PRQR&p=D&b=5&g=0&i=0&r=1668863394516
|
Followers
|
10
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
189
|
|
Created
|
09/18/14
|
Type
|
Free
|
| Moderators | |||
AI
